PRESS RELEASES

Date	Title
Sep 13, 2018	Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
Aug 29, 2018	Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
Aug 7, 2018	Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
Aug 1, 2018	Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
May 29, 2018	Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
May 22, 2018	Ardelyx Announces Pricing of Public Offering of Common Stock
May 21, 2018	Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
May 21, 2018	Ardelyx Announces Proposed Public Offering of Common Stock
May 8, 2018	Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
Mar 19, 2018	Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com